Several brokerages have updated their recommendations and price targets on shares of Bayer AG (NASDAQ: BAYRY) in the last few weeks:

  • 10/2/2017 – Bayer AG was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/25/2017 – Bayer AG was upgraded by analysts at BNP Paribas from a “neutral” rating to an “outperform” rating.
  • 9/22/2017 – Bayer AG was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 9/19/2017 – Bayer AG was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $148.00 price target on the stock. According to Zacks, “Bayer surpassed earnings estimates but missed revenue estimates in the second quarter of 2017. The company experienced a significant decline in sales and earnings in the Crop Science segment due to high channel inventories in Brazil. Business at Consumer Health decreased, primarily due to the difficult market environment in the U.S. Based on this, the company lowered its revenue and earnings outlook for 2017. The company is facing generic threats/competition for many of its products including the Yaz franchise (oral contraceptives). The genericization of key drugs would negatively impact revenues. Nevertheless, the company is looking forward to acquire Monsanto Company in a deal worth approximately $66 billion. With the acquisition, the combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. Yet, Bayer’s shares have outperformed the Zacks classified industry year to date.”
  • 8/25/2017 – Bayer AG was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bayer surpassed earnings estimates but missed revenue estimates in the second quarter of 2017. The company experienced a significant decline in sales and earnings in the Crop Science segment due to high channel inventories in Brazil. Business at Consumer Health decreased, primarily due to the difficult market environment in the U.S. Based on this, the company lowered its revenue and earnings outlook for 2017. The company is facing generic threats/competition for many of its products including the Yaz franchise (oral contraceptives). The genericization of key drugs would negatively impact revenues. Nevertheless, the company is looking forward to acquire Monsanto Company in a deal worth approximately $66 billion. With the acquisition, the combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. Yet, Bayer’s shares have outperformed the Zacks classified industry year to date.”

Shares of Bayer AG (BAYRY) traded up 1.64% during mid-day trading on Wednesday, hitting $34.61. The stock had a trading volume of 164,757 shares. Bayer AG has a 12 month low of $22.88 and a 12 month high of $34.91.

Bayer AG (NASDAQ:BAYRY) last issued its earnings results on Thursday, July 27th. The company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.12. The business had revenue of $13.41 billion for the quarter, compared to analyst estimates of $14.45 billion. Bayer AG had a return on equity of 13.03% and a net margin of 10.90%. Equities analysts expect that Bayer AG will post $2.24 earnings per share for the current year.

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.